←
Walid Macaron, MD MSc161 posts
Walid Macaron, MD MSc avatar

Walid Macaron, MD MSc

@WNMacaron

Heme/Onc Fellow @UTMDAnderson • IM @BCM_InternalMed • MD, MSc in Genetics and Molecular Biology @USJLiban • #GGMU • 🇱🇧

◷ Joined June 2021▧ 17 Photos and videos
Walid Macaron, MD MSc avatar
Walid Macaron, MD MSc@WNMacaron·May 25

Our new review explores how the definition of high-risk Ph+ ALL is shifting across tx eras. Risk is dynamic, shaped by the interplay of biology, response, and treatment context. We examine key determinants, their evolving relevance, and risk-adapted strategies in the current era.

Post attachmentPost attachment
Walid Macaron, MD MSc avatar
Walid Macaron, MD MSc@WNMacaron·23 Oct 2025

• HR Ph- ALL who achieved early NGS MRD neg→favorable long-term survival • HR Ph- ALL and suboptimal MRD dynamics→poor outcomes and benefitted from alloSCT in first remission • Early NGS MRD dynamics can refine risk stratification and may guide consolidative tx decisions

Prof Peter Hotez MD PhD DSc(hon) avatar
⟳ Walid Macaron, MD MSc retweeted
Prof Peter Hotez MD PhD DSc(hon)@PeterHotez·18 Jan 2025

Our ⁦@TXMedCenter⁩ before WWII and today (my photo from a Southwest Airlines flight). Today our Texas Medical Center in Houston is the world’s largest, and also the first biomedicine city of >100,000 employees, >60 institutions, including several medical schools

Post attachmentPost attachment
Rafeh Naqash, MD, FASCO avatar
⟳ Walid Macaron, MD MSc retweeted
Rafeh Naqash, MD, FASCO@thenasheffect·5 Mar 2025

‼️Only data so far of ICI in pts with cardiac Mets. Work led by @AminNassarMD @sarahaboualaiwi @TalalZarif1 out in @jitcancer . A collaboration that spanned several countries and centers. @OUCollegeofMed @StephensonCC @DrChoueiri jitc.bmj.com/content/13/3/e0…

Our new paper in @jitcancer with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. jitc.bmj.com/content/13/3/e0… @thenasheffect @AminNassarMD @sarahaboualaiwi @TalalZarif1 @DrRanaMcKay @DanaFarber

OncoAlert avatar
⟳ Walid Macaron, MD MSc retweeted
OncoAlert@OncoAlert·6 Mar 2025

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study out on JITC buff.ly/iFnRFbO This retrospective, multicenter study examined the safety and clinical outcomes of 110 patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs). The most common cancers were #melanoma (38%) and non-small cell lung cancer #NSCLC (24%), with cardiac metastases frequently located in the atria and ventricles. Cardiac events occurred in 36% of patients, but ICI-related major cardiac adverse events were rare (1.8%). Treatment-related adverse events (trAEs) were common, with 20% experiencing severe (grade ≥3) trAEs. Patients with multiple cardiac metastases had lower response rates to ICI-based therapies. Overall, ICIs showed meaningful efficacy, particularly in melanoma, with no increase in safety risks, highlighting the importance of multidisciplinary management in these complex cases. @AminNassarMD @sarahaboualaiwi @TalalZarif1 @RyanDenu @WNMacaron @Dory_Freeman @Avasbind @salimhayek @ShirlyGrynberg @jennkwanMDPhD @ProfGLongMIA @TarekHaykal1 @Atandondoc @nakhtermd @datsunian @EdwardElAmm @eliekozaily1 @ahmadalhader @boufarhat_elias @mer_herreraMD @chulkimMD @kaushalpar @ADesaiMD @ACortelliniMD @DJPinato @JamesKz_ @nerealiamd @FunchainMD @AChoudharyMD @AartiAsnaniMD @navstruck @ja_ocejo @JTrentMDPhD @DrRanaMcKay @TomasNeilan @DrChoueiri @thenasheffect

Post attachment
Toni Choueiri, MD avatar
⟳ Walid Macaron, MD MSc retweeted
Toni Choueiri, MD@DrChoueiri·5 Mar 2025

Our new paper in @jitcancer with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. jitc.bmj.com/content/13/3/e0… @thenasheffect @AminNassarMD @sarahaboualaiwi @TalalZarif1 @DrRanaMcKay @DanaFarber

ALL Hub avatar
⟳ Walid Macaron, MD MSc retweeted
ALL Hub@ALL_Hub_·9 Dec 2024

CONGRESS #ASH24 | PRESENTATION @WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1. Poorer outcomes occurred in pts with HR B-ALL and slow MRD response. Follow our live feed for more updates: lymphoblastic-hub.com/medica… #ALL #ALLsm

Post attachmentPost attachmentPost attachmentPost attachment